← Back to Search

Chemotherapy

Transferrin Receptor-Targeted Liposomal p53 cDNA for Breast Cancer

Q: What indications is Pembrolizumab typically used to treat?

<p>Pembrolizumab is a medication used to treat <a href="https://www.withpower.com/clinical-trials/cancer">cancer</a>. It can also be used to help patients with microsatellite instability high and unresectable <a href="https://www.withpower.com/clinical-trials/melanoma">melanoma</a> manage their condition.</p>

Phase 1

Waitlist Available

Led By Massimo Cristofanilli, MD, FACP

Research Sponsored by Northwestern University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 24 months

Awards & highlights

Study Summary

This trial is testing a new gene therapy, SGT-53, in combination with immunotherapy and chemotherapy to see if it can help treat patients with metastatic triple negative inflammatory breast cancer.

Eligible Conditions

Breast Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 24 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 24 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Clinical Benefit Rate

Rate of Successful Administration

Secondary outcome measures

Incidence of adverse events

Trial Design

1Treatment groups

Experimental Treatment

Group I: Interventional (SGT-53, pembrolizumab, carboplatin)Experimental Treatment3 Interventions

Patients receive SGT-53 IV over 90-120 minutes on days 1, 8, and 15, pembrolizumab IV over 30 minutes on day 3, and carboplatin IV over 30-60 minutes on day 3. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Carboplatin

FDA approved

Pembrolizumab

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH

13,654 Previous Clinical Trials

40,932,323 Total Patients Enrolled

940 Trials studying Breast Cancer

1,543,360 Patients Enrolled for Breast Cancer

Northwestern UniversityLead Sponsor

1,585 Previous Clinical Trials

917,231 Total Patients Enrolled

39 Trials studying Breast Cancer

12,475 Patients Enrolled for Breast Cancer

Massimo Cristofanilli, MD, FACPPrincipal InvestigatorNorthwestern University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Pembrolizumab a danger to people's health?

"Pembrolizumab received a 1 on our Power scale because there is only limited data supporting its safety and efficacy."

Answered by AI

What indications is Pembrolizumab typically used to treat?

"Pembrolizumab is a medication used to treat cancer. It can also be used to help patients with microsatellite instability high and unresectable melanoma manage their condition."

Answered by AI

How many people are generally chosen to participate in these kinds of drug tests?

"Unfortunately, this study is not enrolling new patients at the moment. The clinical trial was initially posted on October 30th, 2021 but was last edited on October 13th, 2021. However, there are presently 4708 other trials actively recruiting patients with breast cancer and 1606 studies for Pembrolizumab looking for participants."

Answered by AI

Could you please share what other pembrolizumab research has been conducted?

"As of right now, 1606 different clinical trials are investigating pembrolizumab with 315 of those in the third and final stage. The majority of these trials are based in Shanghai, but there are 71781 locations running trials for this treatment globally."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer

2022. "SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05093387.